Catarina Edfjäll

No open positions remaining

61 year

Consumer Services

Health Technology

Profile

Catarina Edfjäll formerly worked at The Cancer Drug Development Forum, as Director from 2008 to 2012, International Collaboration On Rare Diseases & Orphan Drugs, as Director from 2014 to 2021, ObsEva SA, as Independent Director from 2021 to 2024, and CSL Behring AG, as Global Head-Regulatory Affairs from 2013 to 2019.
Dr. Edfjäll received her doctorate degree from the University of Basel and graduate degree from the University of Strasbourg.

Former positions of Catarina Edfjäll

Companies	Position	End
OBSEVA SA	Director/Board Member	2024-03-17
International Collaboration On Rare Diseases & Orphan Drugs	Director/Board Member	2020-12-31
CSL Behring AG CSL Behring AG BiotechnologyHealth Technology Develops biological products	General Counsel	2018-12-31
The Cancer Drug Development Forum The Cancer Drug Development Forum The Cancer Drug Development Forum (CDDF) is a neutral, non-competitive multi-stakeholder platform dedicated to accelerating the development and delivery of effective cancer therapies. The private company is based in Woluwe-Saint-Lambert, Belgium. It brings together patients, academia, pharmaceutical industry members, regulatory agencies, health technology assessment bodies, and patient advocacy groups to foster collaboration, open dialogue, and knowledge sharing in oncology drug development. CDDF organizes conferences, workshops, and webinars on topics such as artificial intelligence in clinical trials, development strategies, patient access, diversity, immuno-oncology, real-world data, and pediatric cancer outcomes. The forum leads initiatives like Accelerating Clinical Trials in the EU (ACT EU) and a diversity initiative to improve clinical trial design and representativeness in research. It publishes white papers, executive summaries, reports, and guidance documents to address challenges and propose solutions for advancing cancer drug development.	Director/Board Member	2011-12-31

See the detail of Catarina Edfjäll's experience

Training of Catarina Edfjäll

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Catarina Edfjäll's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	6
University of Basel University of Basel Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
University of Strasbourg University of Strasbourg Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
CSL Behring AG CSL Behring AG BiotechnologyHealth Technology Develops biological products	Health Technology
ObsEva SA ObsEva SA Pharmaceuticals: MajorHealth Technology Provides therapeutic treatments to increase women's reproductivity	Health Technology
The Cancer Drug Development Forum The Cancer Drug Development Forum The Cancer Drug Development Forum (CDDF) is a neutral, non-competitive multi-stakeholder platform dedicated to accelerating the development and delivery of effective cancer therapies. The private company is based in Woluwe-Saint-Lambert, Belgium. It brings together patients, academia, pharmaceutical industry members, regulatory agencies, health technology assessment bodies, and patient advocacy groups to foster collaboration, open dialogue, and knowledge sharing in oncology drug development. CDDF organizes conferences, workshops, and webinars on topics such as artificial intelligence in clinical trials, development strategies, patient access, diversity, immuno-oncology, real-world data, and pediatric cancer outcomes. The forum leads initiatives like Accelerating Clinical Trials in the EU (ACT EU) and a diversity initiative to improve clinical trial design and representativeness in research. It publishes white papers, executive summaries, reports, and guidance documents to address challenges and propose solutions for advancing cancer drug development.
International Collaboration On Rare Diseases & Orphan Drugs